Navigation Links
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Date:8/21/2007

',getLinkName('Company Sanpshot'));" >LLY) also announced today that it recently submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta for the management of fibromyalgia. The sNDA submission is based on data from approximately 1,400 patients in five clinical trials.

"Lack of awareness of fibromyalgia can lead to frustration as patients often see multiple physicians over a number of years before receiving a formal diagnosis," said Alan Breier, M.D., vice president for medical and chief medical officer, Eli Lilly and Company. "This research may help increase recognition of fibromyalgia and offer hope to those living with this debilitating condition."

About Cymbalta

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on pre-clinical studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the mechanism of action of duloxetine is not fully known, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Cymbalta is approved in the United States for the treatment of major depressive disorder (MDD), the management of diabetic peripheral neuropathic pain (DPNP) and the treatment of generalized anxiety disorder (GAD), all in adults (age 18+). Cymbalta is not approved for use in pediatric patients.

Important Safety Information

Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents and young adults. Pati
'/>"/>

SOURCE Eli Lilly and Company

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
9. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
10. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
11. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... the "Radiology Information Systems Market by Type, Deployment ... & Forecast to 2019" report to their offering. ... is estimated at $501.1 Million 2014, and is projected ... of 7.6% from 2014 to 2019. ...
(Date:9/3/2015)... YORK , Sept. 3, 2015  The findings ... are raising disturbing questions about the company,s handling of ... LLP reports.  On September 2 nd , part ... 300 adverse events, including at least 27 fatalities, have ... disclosed a confidential study commissioned by C.R. Bard in ...
(Date:9/3/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/84p6xc/investigation ... Report on China,s Bromhexine Market, 2010-2019" report to ... incidence of respiratory disease keeps growing and so does ... derivative of vasicine, is a mucolytic agent used in ... viscid or excessive mucus. It can make the phlegm ...
Breaking Medicine Technology:Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Bromhexine Market Report 2015-2019 2
... Oct. 14, 2011 Pregis Corporation, a leading ... products and specialty packaging solutions, announced today that ... to sell its Kobusch-Sengewald business unit to Sun ... adviser to Sun Capital Partners, Inc., for gross ...
... Mass., Oct. 14, 2011 Boston Scientific Corporation (NYSE: ... Medical Device Regulatory Improvement Act, sponsored by Sen. Amy ... and Michael Bennet (D-CO).  The legislation is intended to ... regulatory delays and help new medical technologies safely and ...
Cached Medicine Technology:Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 2Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 3
(Date:9/3/2015)... ... September 03, 2015 , ... NanoCytomics LLC today announced ... company that will bring low-cost cancer pre-screening tests to primary care physicians in ... automated technology platform detects and measures cellular changes at the nanoscale level. The ...
(Date:9/3/2015)... OR (PRWEB) , ... September 03, 2015 , ... ... named the academic partner for the Academy of Integrative Health & Medicine (AIHM) ... under the direction of Tieraona Low Dog, MD, an internationally renowned educator, physician ...
(Date:9/3/2015)... ... September 03, 2015 , ... The Beryl Institute ... 2016, to be held April 13-15 at Sheraton Hotel in Dallas, Texas. Patient ... the collective voices of healthcare leaders, staff, physicians, patients and families across the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., hosted Amsterdam ... his six-month, 10,000 mile journey from Santiago, Chile to Times Square and then ... “Connecting Las Americas” project—Max crossed six countries in 168 days on his 39-year-old ...
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new ... v2, for pre-order on Kickstarter. Today the BedJet v2 pre-order campaign blazed ... top 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use ...
Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3
... Vereen Issues a Call-to-Action for People with Diabetes to ... Diabetes Today, BRIDGEWATER, N.J., Sept. 24 Tony,Award-winning ... a world leader in diabetes care, to launch Take ... to educate,people living with diabetes about their condition. Since ...
... Age 55 and Over to Know the Signs,of ... Suspected, WASHINGTON, D.C., Sept. 24 Despite ... detection, there are,striking differences between intentions and actual ... adults age 55 and over titled, "Alzheimer,s,Disease: Current ...
... Launch of the Disposable flexfit (TM) Breaks down Longstanding Barriers to ... ... N.J., Sept. 24 Songbird Hearing, Inc.,today introduces a unique option ... that 55 million Americans currently,experience some degree of hearing loss, while ...
... Hospital Assets,Patient Care to Remain Uninterrupted At HPA Hospitals, ... America,("HPA" or "the Company") announced today that it and ... Chapter 11,of the U.S. Bankruptcy Code. The filings do ... the HPA system, which continue to operate as usual.,The ...
... The 2008 Compensation Data survey results found that 67.3 percent ... and their family. , ... Kansas ... increases, employers and employees continue to see high health insurance ...
... Drug Administration,s (FDA,s) plan to list those drugs whose safety is ... drug companies, physicians, and patients. , ... Horsham, PA ... the Food and Drug Administration,s (FDA,s) plan to list those drugs ...
Cached Medicine News:Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 2Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 3Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 2Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 3Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 4Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 5Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 2Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 3Health News:Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities 2Health News:Health Insurance Premium Costs High for Employers and Employees 2Health News:DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation 2
... 402 Dilutor-Dispenser is designed to ... in the clinical, biological, and ... reliability and performance as Gilsons ... It is ideal for routine ...
... The 402 Dilutor-Dispenser is ... various applications in the clinical, ... the same reliability and performance ... handling products. It is ideal ...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: